|Phase III||Supportive care, Treatment||Closed||1 to 17||NCI, Other||CDR0000066202|
DFCI-95001, DFCI-FDR001197, NCI-G99-1651, NCT00004034
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known which treatment regimen is more effective for acute lymphoblastic leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy and radiation therapy in treating children who have acute lymphoblastic leukemia.
Further Study Information
OBJECTIVES: I. Compare the efficacy and toxicity of doxorubicin with or without the cardioprotectant drug dexrazoxane in children with high risk acute lymphoblastic leukemia. II. Compare the efficacy and toxicity of hyperfractionated cranial radiation plus standard vs intensive intrathecal chemotherapy in preventing CNS leukemia in standard risk patients. III. Compare the efficacy and toxicity of hyperfractionated vs conventionally fractionated cranial radiation plus standard intrathecal chemotherapy in high risk patients. IV. Compare quality of life of these patients. V. Determine whether molecular evidence of leukemia is present in the bone marrow and peripheral blood at the time of remission induction and during intensification and continuation therapy and whether it disappears, changes over time, and is predictive of relapse.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to risk group (standard risk AND 2 to 8 years AND highest pretreatment WBC less than 20,000/mm3 vs all other standard risk vs high risk). The high risk stratum is further stratified according to dexrazoxane administration (yes vs no). Doxorubicin Investigational Window: Standard risk patients: Patients receive doxorubicin IV on days 0 and 1. High risk patients are randomized to one of two treatment arms: Arm I: Patients receive doxorubicin IV on days 0 and 1. Arm II: Patients receive dexrazoxane IV over 15 minutes immediately followed by doxorubicin IV on days 0 and 1. Induction Therapy for Patients Eligible for Investigational Window: Patients receive oral prednisone or prednisolone or methylprednisolone IV every 6 hours on days 2-30. Patients also receive vincristine IV on days 2, 9, 16, and 23; methotrexate IV over 1 hour on day 2; leucovorin calcium orally or IV every 6 hours beginning 36 hours after methotrexate; and E. coli asparaginase IM on day 4. Intrathecal methotrexate, cytarabine, and hydrocortisone are administered on days 16 and 30. Induction Therapy for Patients Ineligible for Investigational Window: Patients receive the same chemotherapy but at different timing intervals, which are determined by bilirubin levels. Patients who are in hematologic remission on day 30 proceed to CNS treatment. Patients who do not achieve remission by day 30 continue vincristine IV weekly for 3 weeks or until complete remission. Patients who do not achieve remission by day 51 are taken off study. Patients who are in hematologic remission but have CNS blasts on day 30 continue intrathecal chemotherapy, vincristine IV, and asparaginase IM weekly for 3 weeks (days 30, 37, and 44), and doxorubicin IV (with or without dexrazoxane, depending on earlier randomization) on day 30. Cranial radiation is delayed until CSF is clear. CNS Treatment for Standard Risk Patients: Patients receive chemotherapy consisting of vincristine IV for one dose and oral mercaptopurine for 14 days. Patients are then randomized to one of two treatment arms: Arm I: Patients undergo cranial radiotherapy twice a day for 10 days and receive intrathecal methotrexate and cytarabine twice weekly for 2 weeks. Arm II: Patients receive intrathecal methotrexate, cytarabine, and hydrocortisone twice weekly for 2 weeks. Girls with pretreatment WBC less than 20,000/mm3 are nonrandomly assigned to this arm. Patients who refuse randomization undergo conventional radiotherapy daily for 10 days plus receive intrathecal methotrexate and cytarabine twice weekly for 2 weeks. CNS Treatment for High Risk Patients At Least 365 Days Old: Patients receive the same chemotherapy regimen as standard risk patients, plus they receive intrathecal methotrexate and cytarabine twice weekly for 2 weeks. Patients receive doxorubicin with or without dexrazoxane as in the earlier randomization, then are randomized to one of two radiotherapy arms: Arm I: Patients undergo cranial radiotherapy daily for 10 days. Arm II: Patients undergo cranial radiotherapy twice daily for 10 days. Patients who refuse randomization receive therapy as in arm I. Intensification and Continuation Therapy for Patients At Least 365 Days Old: Therapy begins after CNS treatment and at least 3 weeks after complete remission is documented. Standard Risk: Patients receive vincristine IV every 3 weeks, oral prednisone or prednisolone twice a day for five days every 3 weeks, and oral mercaptopurine for 14 days every 3 weeks. E. coli asparaginase IM followed by methotrexate IV or IM are administered weekly for 18 weeks. Treatment is repeated as a 3 week sequence until continuous complete remission has been achieved for 24 months. Patients who had radiotherapy now receive intrathecal methotrexate and cytarabine every 18 weeks, while those patients who did not undergo radiotherapy receive intrathecal methotrexate, cytarabine, and hydrocortisone every 9 weeks for 6 doses, then every 18 weeks. High Risk: Patients receive vincristine, prednisone or prednisolone, mercaptopurine, asparaginase, and methotrexate as for standard risk patients. According to prior randomization, patients also receive doxorubicin IV every 3 weeks or dexrazoxane IV over 15 minutes and doxorubicin IV every 3 weeks. Doxorubicin is continued for 9 months or until the total cumulative dose is reached, then methotrexate IV is administered weekly. Treatment continues as for standard risk patients. Quality of life is assessed on induction day 23, during the second week of CNS therapy or at the start of intensification therapy, during the third week of intensification, during the first week of maintenance therapy (18 months after diagnosis), then every 2 years thereafter. Patients are followed every month for 6 months, every 2 months for 1 year, every 4 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 420 patients will be accrued for this study within 4 years.
DISEASE CHARACTERISTICS: Histologically or cytologically proven acute lymphoblastic leukemia (ALL) No mature B-cell ALL (i.e., surface immunoglobulin present and L3 morphology) Standard risk disease at diagnosis defined as: 1 to 9 years at diagnosis Highest pretreatment WBC less than 50,000/mm3 No blasts on CSF cytospin No T-cell markers on lymphoblasts No anterior mediastinal mass No cranial nerve palsy High risk disease defined as any patient who fails to meet all standard risk criteria at either diagnosis or at end of induction No t(8;14) (q24;q32), t(8;22), or t(2;8) T-cell surface markers and t(8;14) (q24;q11) allowed Investigational Window eligibility: At least 30 days since prior steroid therapy No concurrent emergent mediastinal radiotherapy or intubation No septic shock No concurrent intracranial hemorrhage No clinical evidence of CNS or lung leukostasis Bilirubin less than 1.4 mg/dL
PATIENT CHARACTERISTICS: Age: 1 to 17 Performance status: Not specified Hematopoietic: See Disease Characteristics Hepatic: See Disease Characteristics Renal: Not specified Other: HIV negative
PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No prior chemotherapy Endocrine therapy: See Disease Characteristics No more than 1 week of steroids Radiotherapy: See Disease Characteristics Prior emergent radiotherapy to the mediastinum allowed Surgery: Not specified Other: Prior leukapheresis or exchange transfusion allowed, but must be completed before study
Trial Lead Organizations/Sponsors
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer InstituteNational Cancer Institute
|Stephen E. Sallan||Study Chair|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00004034
ClinicalTrials.gov processed this data on March 16, 2014
Back to Top